Management of Chronic Hepatitis B in Pregnancy: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Basit Öğe Kaydı
dc.authoridSAYAN, MURAT/0000-0002-4374-7193
dc.authoridUral, Onur/0000-0003-1355-7572
dc.authoridAktug Demir, Nazlim/0000-0002-4703-0827
dc.contributor.authorAktug-Demir, Nazlim
dc.contributor.authorAsan, Ali
dc.contributor.authorAyaz, Celal
dc.contributor.authorCelen, Mustafa Kemal
dc.contributor.authorKose, Skran
dc.contributor.authorKuruuzum, Ziya
dc.contributor.authorOrmen, Bahar
dc.date.accessioned2024-09-25T19:57:25Z
dc.date.available2024-09-25T19:57:25Z
dc.date.issued2013
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractStudy Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases set up a task force to develop a consensus report focused on chronic hepatitis B in pregnancy, a complex issue for both the mother with an advanced liver disease and the unborn child who is under the risk of hepatitis B virus (HBV) transmission. Relevant literature and international guidelines were reviewed, and recommendations agreed are presented in the report. An algorithm adapted from actual publications is also proposed for management of chronic hepatitis B in the pregnant patient. Since many women of childbearing age are in the immune tolerant phase of infection, there is generally no need for therapy and no indication to start therapy during the early stages of pregnancy. Initiation of antiviral therapy in the beginning of the third trimester in highly viremic (HBV DNA > 200 000 IU/mL) pregnant women can prevent mother-to-child-transmission of HBV despite postnatal passive and active immunoprophylaxis provided. Given its potency and its high genetic barrier to resistance, tenofovir might be an appropriate option for mothers who might need to continue their treatment for active hepatitis B after delivery.en_US
dc.identifier.doi10.5152/kd.2013.14
dc.identifier.endpage19en_US
dc.identifier.issn1301-143X
dc.identifier.issn1309-1484
dc.identifier.issue1en_US
dc.identifier.startpage12en_US
dc.identifier.urihttps://doi.org/10.5152/kd.2013.14
dc.identifier.urihttps://hdl.handle.net/20.500.12491/13411
dc.identifier.volume26en_US
dc.identifier.wosWOS:000420932800003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.institutionauthorSaltoglu, Nese
dc.language.isotren_US
dc.publisherDoc Design Informatics Co Ltden_US
dc.relation.ispartofKlimik Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzYK_20240925en_US
dc.subjectChronic hepatitis Ben_US
dc.subjectpregnancyen_US
dc.subjectantiviral agentsen_US
dc.titleManagement of Chronic Hepatitis B in Pregnancy: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseasesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu